Free Newsletter
J&J's Topamax helps alcoholics quit
What do you call a migraine drug that could help alcoholics quit drinking? A big-time marketing opportunity--if it weren't going off patent next year.
A new study shows that the Johnson & Johnson remedy Topamax, used in epilepsy and migraine, can help alcoholics stop craving liquor. The study was funded in part by the company, but it says it doesn't plan to seek FDA approval for its use against alcoholism. Doctors could prescribe it off-label, however.
J&J didn't put out a press release touting the research, perhaps because that could be construed as promoting the drug for an off-label use. The study, published in the Journal of the American Medical Association, will take care of that--with the help of all the attendant media attention. Including ours.
- check out the article from the Washington Post
Related Articles:
Compound found for reducing alcohol dependence. Report
Drug companies focusing on ending alcohol abuse. Report
Topamax approved for new indication. Report
Read more on: Johnson & Johnson
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment